Is it feasible to treat polycystic ovarian syndrome with or without insulin resistance using glucokinase activators as novel hypoglycaemic medications? A protocol for a systematic review and meta-analysis
Introduction A variety of hypoglycaemic drugs are used to treat polycystic ovarian syndrome (PCOS), but their efficacy remains insufficient. Glucokinase activators (GKAs) are a unique class of hypoglycaemic medications with emerging potential, notably in significantly reducing insulin resistance (IR...
Saved in:
Main Authors: | Xiaojing Liu, Lei Zeng, Shuo Yuan, Genping Zeng, Xijing Lu, Peiyin Li, Tan Zeng, Zitong Lin, Yuxi Miao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-12-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/14/12/e088484.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Serum Zinc Levels in Women with Polycystic Ovarian Syndrome are Lower as Compared to Those without Polycystic Ovarian Syndrome: A Cohort Study
by: Swati Dhar, et al.
Published: (2024-01-01) -
The Effect of Time-Restricted Eating on Insulin Levels and Insulin Sensitivity in Patients with Polycystic Ovarian Syndrome: A Systematic Review
by: R. Floyd, et al.
Published: (2022-01-01) -
Dynamic localization of glucokinase and its regulatory protein in hypothalamic tanycytes.
by: Magdiel Salgado, et al.
Published: (2014-01-01) -
Prevalence Of Skin Manifestations In Patients With Polycystic Ovarian Syndrome
by: Tehseen Naveed, et al.
Published: (2024-03-01) -
From Placenta to Polycystic Ovarian Syndrome: The Role of Adipokines
by: Chiara Sartori, et al.
Published: (2016-01-01)